Unity Biotechnology’s corporate restructuring is a cash-saving move that allows the company to focus resources on its lead program, a drug in Phase 2 testing for diabetic macular edema and wet age-related macular degeneration. Unity previously restructured in 2020 following the Phase 2 failure of its osteoarthritis drug.
